Literature DB >> 24434398

Adaptation and implementation of the "Kidney Disease: Improving Global Outcomes (KDIGO)" guidelines for evaluation and management of mineral and bone disorders in chronic kidney disease for practice in the Middle East countries.

Mona Al Rukhaimi1, Ali Al Sahow, Yousef Boobes, David Goldsmith, Jose Khabouth, Tarek El Baz, Hisham Mahmoud, Mohammad Reza Ganji, Faissal A M Shaheen.   

Abstract

This review presents the views of an expert group of nephrologists from the Middle East along with an international expert on adaptation and implementation of the 2009 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for evaluation and manage-ment of mineral and bone disorders in chronic kidney disease (CKD-MBD) for practice in the Middle East countries. The members of the panel examined the KDIGO guidelines and formulated recommendations that can be implemented practically for the management of CKD-MBD in the Middle East. There was a broad agreement on most of the recommendations made by the KDIGO work-group. However, the panelists commented on specific areas and amplified certain concepts that might help the nephrologists in the Middle East. The final document was reviewed by all participants as well as by members of the Middle East task force implementation group for KDIGO guidelines. Their comments were incorporated. The guideline statements are presented along with detailed rationale and relevant discussion as well as limitations of the evidence. The panel recognized the need to upgrade the suggestion of KDIGO related to lateral abdominal radiograph and echocardiogram in patients with CKD stages 3-5D into a stronger recommendation. The panel underlined the risk of hyper-phosphatemia to CKD-MBD and the importance of prompt initiation or modification of therapy according to rising trends in para-thyroid hormone level. They recommended the use of non-calcium-based phosphate binders as the first-line therapy in CKD patients with signs of vascular calcification. The panel agreed that all aspects of the KDIGO recommendations concerning bone biopsy, evaluation and treatment of bone disease after kidney trans-plantation should be implemented as such.

Entities:  

Mesh:

Year:  2014        PMID: 24434398     DOI: 10.4103/1319-2442.124536

Source DB:  PubMed          Journal:  Saudi J Kidney Dis Transpl        ISSN: 1319-2442


  3 in total

1.  Use of 99mTc-sestamibi SPECT/CT imaging in predicting the degree of pathological hyperplasia of the parathyroid gland: semi-quantitative analysis.

Authors:  Junhao Ma; Jun Yang; Chuanzhi Chen; Yimin Lu; Zhuochao Mao; Haohao Wang; Yan Yang; Zhongqi Li; Weibin Wang; Lisong Teng
Journal:  Quant Imaging Med Surg       Date:  2021-10

2.  FGF23 neutralization improves bone quality and osseointegration of titanium implants in chronic kidney disease mice.

Authors:  Ningyuan Sun; Yuchen Guo; Weiqing Liu; Michael Densmore; Victoria Shalhoub; Reinhold G Erben; Ling Ye; Beate Lanske; Quan Yuan
Journal:  Sci Rep       Date:  2015-02-10       Impact factor: 4.379

3.  Pattern of Laboratory Parameters and Management of Secondary Hyperparathyroidism in Countries of Europe, Asia, the Middle East, and North America.

Authors:  Mario Cozzolino; Eugeniy Shilov; Zuo Li; Masafumi Fukagawa; Saeed M G Al-Ghamdi; Ronald Pisoni; Brian Bieber; Bhadrish Vallabh; Deepa H Chand
Journal:  Adv Ther       Date:  2020-05-14       Impact factor: 3.845

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.